RADIANCE: Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT03137264

Collaborator

Medpace, Inc. (Industry)

Enrollment

Locations

12.6

Actual Duration (Months)

1.9

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study is being done to determine if non-invasive testing (urine and plasma testing) is as effective as tissue testing in identifying epidermal growth factor receptor (EGFR) T790M mutation status. EGFR is a type of protein found on the surface of cells in the body. When this protein is mutated and becomes too active, it can lead to cancer growth. T790M is a mutation that develops in response to treatment of the EGFR mutation.

Participating patients will have tumor tissue (via cobas test), as well as 2 plasma samples (via cobas and Guardant360 tests) and 1 urine sample (via Trovera test), tested for EGFR T790M mutation status. If the results of the cobas tissue and/or plasma test show that a patient is T790M positive, they will be treated according to standard of care, which may include treatment with osimertinib. Osimertinib is approved for use in the United States for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).

Condition or Disease	Intervention/Treatment	Phase
Non-small Cell Lung Cancer	Drug: Other

Detailed Description

RADIANCE is an open-label, prospective biomarker study to assess analytic concordance between non-invasive testing (plasma and urine) and tissue testing for the EGFR T790M mutation. All patients will have tumor tissue (via cobas test) as well as 2 plasma samples (via cobas and Guardant360) and 1 urine sample (via Trovera) tested for the EGFR T790M mutation (Part 1). Patients who are confirmed T790M negative based on both cobas biomarker tests (tissue and plasma) will have completed the study. Patients who demonstrate T790M+ on cobas tissue and/or cobas plasma testing may choose to undergo treatment with osimertinib in consultation with their healthcare provider (no investigational product will be provided for this study) and will continue to Part 2. In case of insufficient samples for biomarker testing or invalid results from any of the 4 testing modalities, another sample may be acquired from the patient, if feasible, including the patient's decision to undergo a second biopsy. Failure of a patient to undergo a tissue, plasma, or urine sample collection for biomarker testing will result in their withdrawal from the study. If 1 or more samples are insufficient for testing or 1 or more of the test results are invalid, the patient may still qualify for the clinical outcomes part of the study (Part 2) as long as cobas tissue and/or cobas plasma test is T790M+ and the patient receives at least one dose of osimertinib.

During Part 2 Follow-Up Visits will occur according to standard of care, but at least every 12 weeks for the first 12 months of treatment. A Final Study Visit will occur at 18 months (Week 72 +/- 14 days) or upon early withdrawal.

Statistical methods Sample size: The sample size is such to provide enough statistical precision for the primary endpoint. A sample size of 400 patients with evaluable biomarker test results for analytic concordance has been selected in order to achieve a precision of no more than ±5% around the estimated concordance rate. If a 15% inflation factor is applied (~70 patients) to this sample size to take into account those patients who may not be evaluable for concordance estimates, a total of approximately 470 patients will be enrolled.

The Full Analysis Sets will include the following:

Part 1: All patients in the study with cobas tissue, Guardant360 plasma, and Trovera urine test results.

Part 2: Patients who demonstrate T790M+ cobas tissue and/or cobas plasma testing and were treated with at least 1 dose of osimertinib (i.e., all patients in Part 2).

Safety analysis sets: The safety analysis sets will include the following:

Part 1: All patients in the study from the time of informed consent until completion of Part 1.

Part 2: Patients who demonstrate T790M+ cobas tissue and/or cobas plasms testing and were treated with at least 1 dose of osimertinib (i.e., all patients in Part 2).

The analyses of the data collected within this study will be descriptive only, with no formal statistical testing. Continuous variables will be summarized by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarized by frequency counts and percentages for each category. A Statistical Analysis Plan will be prepared and finalized prior to the first interim analysis, which will occur upon completion of the diagnostic analytic validity part of the study (Part 1). The concordance rate between non-invasive testing and cobas tissue testing will be presented as the point estimate together with the exact 95% confidence interval (CI) estimated using the Clopper-Pearson method. The ORR will be presented as the point estimate together with the exact 95% CI according to the Clopper-Pearson method. The duration of response (DoR) and progression-free survival (PFS) will be presented for all patients in Part 2, summarized using the Kaplan-Meier (K-M) method with associated K-M curves. The median DoR and PFS will be presented, as well as the rates at clinically relevant time points, together with the associated 95% CIs.

Study Design

Study Type:

Observational

Actual Enrollment :

44 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer

Actual Study Start Date :

Oct 24, 2017

Actual Primary Completion Date :

Nov 10, 2018

Actual Study Completion Date :

Nov 10, 2018

Arms and Interventions

Arm	Intervention/Treatment
T790M positive Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.	Drug: Other Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib. Other Names: Standard of Care
T790M negative Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.

Arm

Intervention/Treatment

T790M positive

Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.

Drug: Other

Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.

Other Names:

Standard of Care

T790M negative

Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.

Outcome Measures

Primary Outcome Measures

The percentage of patients whose T790M results on Trovera urine AND Guardant360 plasma testing match their T790M results on cobas tissue testing. [Visit 1 (Day-21 to Day 0)]
The Overall Percent Agreement will be estimated as analytic concordance between Guardant360 plasma and Trovera urine testing versus cobas tissue testing in identifying T790M status (positive or negative). The Positive Percent Agreement will be estimated as the percentage of cobas tissue positive patients who are also Guardant360 plasma and/or Trovera urine positive. The Negative Percent Agreement will be estimated as the percentage of cobas tissue negative patients who are also Guardant360 plasma and Trovera urine negative.

Secondary Outcome Measures

Objective Response Rate (ORR) [Every 12 weeks for 12 months]
The number of patients achieving a confirmed partial response or complete response per RECIST 1.1 from treatment with osimertinib.
Duration of Response (DoR) [Every 12 weeks for the first 12 months, then at week 72]
The time from first documented tumor response defined by RECIST 1.1 from osimertinib treatment until the date of documented progression or death from any cause.
Progression Free Survival (PFS) [Every 12 weeks for the first 12 months, then at Week 72]
Defined as the time from date of first dose of osimertinib until the date of disease progression by RECIST 1.1 or death by any cause.

Other Outcome Measures

Number of procedure-related adverse events and Serious Adverse Events (SAEs) [Up to 8 weeks after Visit 1]
To evaluate safety and tolerability of study procedures.
Percentage of patients whose Trovera urine OR Guardant360 plasma T790M results are the same as their cobas tissue T790M results. [Visit 1 (Day -21 to Day 0)]
The overall percent agreement will be estimate as analytic concordance between cobas tissue and Guardant360 plasma, and cobas tissue and Trovera urine testing in identifying T790M status. The positive percent agreement will be estimated as the percentage of cobas tissue positive patients who are also Guardant360 plasma positive and cobas tissue positive patients who are Trovera urine positive. The negative percent agreement will be estimated as the percentage of cobas tissue negative patients who are also Guardant360 plasma negative and cobas tissue negative patients who are Trovera urine negative.
The presence of additional biomarkers from the blood and/or urine of NSCLC patients who have progressed during or following treatment with an EGFR tyrosine kinase inhibitor [Visit 1 (Day -21 to Day 0)]
Biomarker results will be assessed and may be compared to T790M status and/or clinical response.
Percentage of patients whose Trovera urine OR Guardant360 plasma EGFR mutation results are the same as their cobas tissue EGFR mutation results. [Visit 1 (Day -21 to Day 0)]
The overall percent agreement will be estimated as analytic concordance between Guardany360 plasma and Trovera urine testing versus cobas tissue testing in identifying the status of specified EGFR mutations. The positive percent agreement will be estimated as the percentage of cobas tissue positive patients who are also Guardant360 plasma and/or Trovera urine positive. The negative percent agreement will be estimated as the percentage of cobas tissue negative patients who are also Guardant360 plasma and Trovera urine negative.
Physical Exam [Up to 8 weeks after Visit 1]
Changes in physical exams from baseline
Vital signs [Up to 8 weeks after Visit 1]
Changes in vital signs from baseline
ECG [Up to 8 weeks after Visit 1]
Changes in ECGs from baseline.
Number of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest [From the time of first dose of osimertinib through 30 days past the last dose of osimertinib or 30 days after Week 72, if osimertinib treatment remains ongoing at Week 72.]
To evaluate the safety and tolerability of osimertinib.
Physical Exam [From the time of first dose of osimertinib through the date of last dose of osimertinib or at Week 72, whichever comes first.]
To evaluate the safety and tolerability of osimertinib.
Vital signs [From the time of first dose of osimertinib through the date of last dose of osimertinib or at Week 72, whichever comes first.]
To evaluate the safety and tolerability of osimertinib
ECG [From the time of first dose of osimertinib through the date of last dose of osimertinib or at Week 72, whichever comes first.]
To evaluate the safety and tolerability of osimertinib

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 130 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of informed consent prior to any study-specific procedures
Females and males >/= 18 years
Primary diagnosis of NSCLC with evidence of disease progression during or following treatment with an EGFR tyrosine kinase inhibitor (diagnosis of NSCLC that is confirmed by cytology is acceptable)
Willing to undergo tumor biopsy (e.g., excision, core biopsy, or endoscopic biopsy), preferably of a progressing lesion, and provide blood and urine for biomarker testing
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Exclusion Criteria:

Involvement in the planning and/or conduct of the study
Prior treatment with osimertinib or another T790M directed therapy
Current participation in another clinical study with an investigational product or patients who plan to receive any treatment that is not FDA-approved for EGFR mutation positive NSCLC at any time during the course of this study
Use of any chemotherapeutic agent within 1 week of tissue, plasma, and urine sample collection
For women - currently pregnant or plan to become pregnant during the course of the study: pre-menopausal women of childbearing potential must have a urine or serum pregnancy test performed during the screening/enrollment period and prior to initiating anti-cancer treatment
Judgment by the investigator that the patient should not participate in the study due to the patient being unlikely to comply with study procedures, restrictions, and requirements, such as in the case of severe or uncontrolled systemic disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Anaheim	California	United States	92801
2	Research Site	Los Angeles	California	United States	90017
3	Research Site	Saint Helena	California	United States	94574
4	Research Site	Santa Rosa	California	United States	95403
5	Research Site	Deerfield Beach	Florida	United States	33442
6	Research Site	Fort Lauderdale	Florida	United States	33308
7	Research Site	Honolulu	Hawaii	United States	96819
8	Research Site	Boise	Idaho	United States	83706
9	Research Site	Chicago	Illinois	United States	60612
10	Research Site	Harvey	Illinois	United States	60426
11	Research Site	Annapolis	Maryland	United States	21401
12	Research Site	Southfield	Michigan	United States	48075
13	Research Site	Brick	New Jersey	United States	08724
14	Research Site	Farmington	New Mexico	United States	87401
15	Research Site	White Plains	New York	United States	10601
16	Research Site	Asheville	North Carolina	United States	28801
17	Research Site	Hendersonville	North Carolina	United States	28792
18	Research Site	Kettering	Ohio	United States	45409
19	Research Site	Seattle	Washington	United States	98101
20	Research Site	Seattle	Washington	United States	98109
21	Research Site	Edmonton	Alberta	Canada	T6G 1Z2
22	Research Site	Newmarket	Ontario	Canada	L3Y 2P9
23	Research Site	Montreal	Quebec	Canada	H1T 2M4